Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7,973 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
Arora S, O'Brien C, Zeuzem S, Shiffman ML, Diago M, Tran A, Pockros PJ, Reindollar RW, Gane E, Patel K, Wintfeld N, Green J. Arora S, et al. Among authors: green j. J Gastroenterol Hepatol. 2006 Feb;21(2):406-12. doi: 10.1111/j.1440-1746.2005.04059.x. J Gastroenterol Hepatol. 2006. PMID: 16509866 Clinical Trial.
Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J. Sullivan SD, et al. Among authors: green j. Am J Gastroenterol. 2004 Aug;99(8):1490-6. doi: 10.1111/j.1572-0241.2004.30286.x. Am J Gastroenterol. 2004. PMID: 15307866
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
Rasenack J, Zeuzem S, Feinman SV, Heathcote EJ, Manns M, Yoshida EM, Swain MG, Gane E, Diago M, Revicki DA, Lin A, Wintfeld N, Green J. Rasenack J, et al. Among authors: green j. Pharmacoeconomics. 2003;21(5):341-9. doi: 10.2165/00019053-200321050-00005. Pharmacoeconomics. 2003. PMID: 12627987 Clinical Trial.
7,973 results